Currently out of the existing stock ratings of Bruce Jackson, 145 are a BUY (89.51%), 16 are a HOLD (9.88%), 1 are a SELL (0.62%).

Bruce Jackson

Work Performance Price Targets & Ratings Chart

Analyst Bruce Jackson, currently employed at BENCHMARK, carries an average stock price target met ratio of 48.85% that have a potential upside of 40.45% achieved within 157 days.

Bruce Jackson’s has documented 291 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on HUMA, Humacyte at 14-May-2025.

Wall Street Analyst Bruce Jackson

Analyst best performing recommendations are on GNLX (GENELUX COMMON STOCK).
The best stock recommendation documented was for BFRI (BIOFRONTERA) at 12/16/2021. The price target of $220 was fulfilled within 5 days with a profit of $82 (59.42%) receiving and performance score of 118.84.

Average potential price target upside

of $30.2 (55.44%) on CLNN (CLENE).
of $23.78 (107.52%) on BLTE (BELITE BIO ADR).
of $16.15 (63.51%) on HRTX (HERON THERAPEUTI).

CEMI Chembio Diagnostics FLXN Flexion Therapeutics HBIO Harvard Bioscience NEO NeoGenomics NVTA Invitae Corp OCX OncoCyte Corp SEEL Seelos Therapeutics SKIN Beauty Health Co STAA STAAR Surgical Company EXAS EXACT Sciences MDXG MiMedx Group BFRA Biofrontera AG CLNN Clene UNCY Unicycive Therapeutics AXGN Axogen BFRI Biofrontera BIOL BIOLASE BLTE Belite Bio ADR HOTH Hoth Therapeutics HRTX Heron Therapeuti MODD Modular Medical HUMA Humacyte MLSS Milestone Scientific RVPH Reviva Pharmaceuticals Holdings GNLX Genelux Common Stock TNON Tenon Medical

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Kyle Bauser (LAKE STREET)